Psoriatic arthritis registries

Piercarlo Sarzi-Puttini, Valentina Varisco, Maria Chiara Ditto, Maurizio Benucci, Fabiola Atzeni

Research output: Contribution to journalArticlepeer-review

Abstract

The introduction of new biological drugs for the treatment of rheumatoid arthritis and spondyloarthritis has led to the creation of a number of registries in Europe and the United States. Most of them are sponsored by national rheumatology societies, and provide information that is useful in clinical practice concerning the clinical characteristics, efficacy, and safety of all licensed biological drugs. Their findings also help to improve our understanding of the quality of life and working ability of patients receiving biological drugs, and suggest methods for allocating resources. However, there are only a few registries for psoriatic arthritis, and efforts should be made to increase their number to obtain further reliable and useful data. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)30-32
Number of pages3
JournalJournal of Rheumatology
Volume93
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • Adverse events
  • Biological drugs
  • Psoriatic arthritis
  • Registries

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Psoriatic arthritis registries'. Together they form a unique fingerprint.

Cite this